US equities |
MU $979.17 ▲+5.43% META $611.95 ▼-1.33% TSLA $403.43 ▼-0.99% SPCX $144.51 ▼-2.74% NVDA $216.35 ▼-0.73% SNDK $1,397.97 ▲+7.14% GOOGL $324.30 ▲+1.16% AMD $576.03 ▲+2.81%
FinancialContent

Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

0.5200 +0.0093 (+1.82%)
Delayed Quote Updated: 2:24 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tempest Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companies 
From Tempest Therapeutics
Via GlobeNewswire
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Unusual volume stocks in Friday's session ↗
Via Chartmill
Top movers in Thursday's session ↗
Via Chartmill
Which stocks have an unusual volume on Thursday? ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
These stocks have an unusual volume in today's session ↗
Via Chartmill
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
Discover the top movers in Wednesday's pre-market session. ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
From Tempest Therapeutics
Via GlobeNewswire
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
From Tempest Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >